BC
ITCI

Brookfield Corp’s Intra-Cellular Therapies Inc. ITCI Stock Holding History

Brookfield Corp’s Portfolio ITCI Stock Details ITCI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q3 		– Sell
-29,323
Closed -$1.86M – 547
2023
Q2 		$1.86M Sell
29,323
-64,824
-69% -$4.04M 0.01% 414
2023
Q1 		$5.1M Buy
94,147
+64,202
+214% +$3.1M 0.02% 286
2022
Q4 		$1.58M Sell
29,945
-18,817
-39% -$943K 0.01% 443
2022
Q3 		$2.27M Buy
+48,762
New +$2.55M 0.01% 434
2022
Q2 		– Sell
-25,540
Closed -$1.56M – 767
2022
Q1 		$1.56M Buy
+25,540
New +$1.33M 0.01% 431

Other funds holding ITCI

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
WA
Wasatch Advisors Salt Lake City, Utah $15.3B AUM 25.06% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.75B AUM 68.58% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Brookfield Corp's ITCI Position: Q3 2023 in Review

Brookfield Corp sold out of Intra-Cellular Therapies Inc. (ITCI) in Q3 2023, closing a stake of 29,323 shares — an estimated $1.86M sold.

Brookfield Corp first reported a position in ITCI in Q1 2022 and held it in 5 quarters. The position peaked at $5.1M in Q1 2023. 292 funds tracked by Wall St. Rank hold ITCI as of Q3 2023.

  • Brookfield Corp reported no remaining Intra-Cellular Therapies Inc. position as of Q3 2023 after selling out during the quarter.
  • Brookfield Corp sold 29,323 Intra-Cellular Therapies Inc. shares in Q3 2023, an estimated $1.86M.
  • Brookfield Corp first reported a position in Intra-Cellular Therapies Inc. in Q1 2022 and held it in 5 quarters.
  • Brookfield Corp's Intra-Cellular Therapies Inc. position peaked at $5.1M in Q1 2023.
  • 292 funds tracked by Wall St. Rank held Intra-Cellular Therapies Inc. as of Q3 2023.

Based on Brookfield Corp's 13F filing for Q3 2023, filed 14 Nov 2023.